Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

28.82 6.03

Buy Sell

Overview

Share price change

24h

Current

Min

27.13

Max

29.05

Key metrics
By Trading Economics
Income	-270M 3.6M
Sales	-16M 268M
P/E Sector Avg	11.588 68.51
EPS	0.02
Profit margin	1.357
Employees	796
EBITDA	-19M 7M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+24.01% upside

Dividends
By Acuity
Next Earnings	4 Nov 2026

Market Stats
By TradingEconomics
Market Cap	586M 4.4B
Previous open	22.79
Previous close	28.82

News Sentiment

By Acuity

50%

175 / 340 Healthcare

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2026, 23:01 UTC

News

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

3 Aug 2026, 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

31 Jul 2026, 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

30 Jul 2026, 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

29 Jul 2026, 20:41 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading amid a broader market decline linked to rising crude oil prices and geopolitical tensions.

28 Jul 2026, 20:06 UTC

ACADIA Pharmaceuticals is rising amid strong performance in the Biotechnology sector. The stock is nearing the upper end of its one-month range.

27 Jul 2026, 20:01 UTC

ACADIA Pharmaceuticals Inc. shares are higher today, continuing an upward trend since Friday's close, despite no specific news driving the price movement.

24 Jul 2026, 19:56 UTC

ACADIA Pharmaceuticals shares are higher since Thursday's close, despite a dip earlier in the session. The stock remains below its 20-day moving average.

23 Jul 2026, 10:06 UTC

ACADIA Pharmaceuticals is trading higher in pre-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

22 Jul 2026, 22:16 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading, with unusual activity noted. Broader market concerns may be influencing investor sentiment.

21 Jul 2026, 23:16 UTC

ACADIA Pharmaceuticals Inc. shares traded roughly flat in after-market hours, remaining near the upper end of their one-month trading range.

20 Jul 2026, 19:56 UTC

Event

News

Social Media

Acadia Pharmaceuticals received Fast Track designation for remlifanserin, but shares are lower today, continuing a trend of declines over the past three sessions.

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

24.01% upside

12 Months Forecast

Average 33.67 USD 24.01%

High 38 USD

Low 25 USD

Based on 16 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

175 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.